Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 16, pp. 4268-4279
Open Access | Times Cited: 167

Showing 26-50 of 167 citing articles:

The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities
Bianca Garlisi, Sylvia Lauks, Caroline Aitken, et al.
Current Oncology (2024) Vol. 31, Iss. 7, pp. 3826-3844
Open Access | Times Cited: 11
Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer
Chenying Liu, Xiaolong Qian, Chunyan Yu, et al.
Cancer Letters (2024) Vol. 586, pp. 216642-216642
Closed Access | Times Cited: 8
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
Elizabeth K. Lee, Ursula A. Matulonis
Cancers (2020) Vol. 12, Iss. 8, pp. 2054-2054
Open Access | Times Cited: 64
New approaches for targeting platinum-resistant ovarian cancer
Michelle McMullen, Ainhoa Madariaga, Stéphanie Lheureux
Seminars in Cancer Biology (2020) Vol. 77, pp. 167-181
Closed Access | Times Cited: 61
PARP Inhibitors in Cancer Diagnosis and Therapy
Chung Ying Chan, Kel Vin Tan, Bart Cornelissen
Clinical Cancer Research (2020) Vol. 27, Iss. 6, pp. 1585-1594
Open Access | Times Cited: 61
PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers
Elizabeth K. Lee, Panagiotis A. Konstantinopoulos
Therapeutic Advances in Medical Oncology (2020) Vol. 12
Open Access | Times Cited: 51
Driving Immune Responses in the Ovarian Tumor Microenvironment
Franklin Ning, Christopher B. Cole, Christina M. Annunziata
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 41
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Olivier Michielin, Aly‐Khan A. Lalani, Caroline Robert, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e003024-e003024
Open Access | Times Cited: 35
Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents
Federica Martorana, Leandro Apolinário da Silva, Cristiana Sessa, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 953-953
Open Access | Times Cited: 29
Gasdermin C sensitizes tumor cells to PARP inhibitor therapy in cancer models
Shuanglian Wang, Chiung-Wen Chang, Juan Huang, et al.
Journal of Clinical Investigation (2023) Vol. 134, Iss. 1
Open Access | Times Cited: 21
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
Chun Wai Wong, Christos Evangelou, Kieran N. Sefton, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 20
Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
Ana Veneziani, Clare L. Scott, Matthew J. Wakefield, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 16
Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
Brigida Anna Maiorano, Mauro Francesco Pio Maiorano, Evaristo Maiello
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 16
Immunotherapy for Ovarian Cancer: Disappointing or Promising?
Mengqi Deng, Fan Tang, Xiangyu Chang, et al.
Molecular Pharmaceutics (2024) Vol. 21, Iss. 2, pp. 454-466
Closed Access | Times Cited: 7
Adoptive T cell therapy for ovarian cancer
Sarah B. Gitto, Chibuike Ihewulezi, Daniel J. Powell
Gynecologic Oncology (2024) Vol. 186, pp. 77-84
Closed Access | Times Cited: 7
Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies
Aleksandra Klemba, Lubomir Bodnar, Halina Waś, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 24, pp. 9492-9492
Open Access | Times Cited: 41
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
Hélène Vanacker, Philipp Harter, Sana Intidhar Labidi‐Galy, et al.
Cancer Treatment Reviews (2021) Vol. 99, pp. 102255-102255
Open Access | Times Cited: 38
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
Claudia Dominici, Nicolas Sgarioto, Zhenbao Yu, et al.
Clinical Epigenetics (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 37
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer
Jenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 11, pp. e003609-e003609
Open Access | Times Cited: 35
PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data
Myrto Moutafi, Panagiota Economopoulou, David L. Rimm, et al.
Oral Oncology (2021) Vol. 117, pp. 105292-105292
Closed Access | Times Cited: 34
Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
Jue Zhu, Lifeng Yan, Qiming Wang
Journal of Ovarian Research (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 34
PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers
Tiantian Wu, Caijin Tang, Renchuan Tao, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 34
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents
Jitka Fučíková, Lenka Palová-Jelínková, Vanessa Klapp, et al.
Trends in cancer (2022) Vol. 8, Iss. 5, pp. 426-444
Open Access | Times Cited: 26
The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
Brigida Anna Maiorano, Domenica Lorusso, Mauro Francesco Pio Maiorano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3871-3871
Open Access | Times Cited: 26
Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Robert L. Hollis, Alison Meynert, Caroline O. Michie, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 16, pp. 3546-3556
Open Access | Times Cited: 26

Scroll to top